Functional immune characterization of HIV-associated non-small-cell lung cancer.
Dalla Pria, A
Annals of oncology : official journal of the European Society for Medical Oncology
MetadataShow full item record
Pinato, D., Kythreotou, A., Mauri, F., Suardi, E., Allara, E., Shiner, R., Akarca, A., et al. (2018). Functional immune characterization of HIV-associated non-small-cell lung cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 29 (6), 1486-1488. https://doi.org/10.1093/annonc/mdy125
Dear Editor, In the combined anti-retroviral therapy (cART) era, non-small cell lung cancer (NSCLC) is a highly incident cause of morbidity and mortality in people living with HIV (PLHIV). The immune-pathogenesis of NSCLC and HIV infection both rely on programmed-death 1 (PD-1) receptor-ligand interaction as a mechanism to induce T-cell exhaustion. To date, PLHIV have been excluded from clinical trials of immune-checkpoint inhibitors (ICPI), on the presumption that anti-tumour immunity might be compromised by HIV infection. To verify this, we evaluated the clinico-pathologic significance of PD-ligands expression in a consecutive series of 221 archival NSCLC samples, 24 of which were HIV-associated (Table S1).
Lymphocytes, Tumor-Infiltrating, Humans, HIV, HIV Infections, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prognosis, Biomarkers, Tumor, B7-H1 Antigen
External DOI: https://doi.org/10.1093/annonc/mdy125
This record's URL: https://www.repository.cam.ac.uk/handle/1810/277893